Want to hear about what we have been up to this last year?
Author Archive for: Sofia Lindén
About Sofia Lindén
Sofia Lindén is responsible for producing the content for digital communications in the cluster, including articles, photographs and videos for the websites and social media platforms.
She has previously worked at the Nordic publishing company Orage as Swedish Print Editor and Digital Project Manager. She also holds a master degree in International Journalism from City University London. Find out more about Sofia by visiting her LinkedIn.
Entries by Sofia Lindén
Professor Johanna Olweus has been awarded the ERC Consolidator Grant for her cancer research project on immunotherapy.
Our school collaboration project inspires science and health communication.
DNB are promoting start-ups in the Nordic healthcare sector!
We want to accelerate cancer research in T cell immunotherapy!
PCI Biotech reveals they have been collaborating with Astra Zeneca since 2015. Our member PCI Biotech grabbed the opportunity during their third quarter report this week to announce who their mystery collaboration partner since 2015 has been. The “top-ten pharma company in the world”, who has been helping them, is Astra Zeneca. PCI Biotech is […]
Read some of the exciting Q3 developments from our members.
Did you miss EHiN this year? Read our short summary of the highlights relating to cancer research.
Oslo Cancer Cluster Incubator has joined a new national health mentor program to help Norwegian startups connect with the right experts.
From a relatively modest podcast to packed live shows at Arendalsuka, Radium has in three years grown into a leading cancer podcast in Norway.
EHiN is important in order to realise the opportunities that digital technologies can give patients, society and industry.
Our member Targovax has announced a new clinical trial for skin cancer patients at Oslo University Hospital. The second part of a clinical trial for patients with refractory advanced melanoma (a type of skin cancer) will take place at Oslo University Hospital. “We are excited that we can offer this treatment alternative to patients in […]
Ullern Upper Secondary School and Oslo Cancer Cluster are paving the way for students to become the cancer researchers of the future.
Emerging therapies, digital solutions and AI were central topics when international experts met during the oncology session at the Nordic Life Science Days 2019.
The biggest key players from the life science industry in Norway came together to promote Nordic collaboration.
During Arendalsuka 2019, we arranged a breakfast meeting on the development of cancer treatments of the future, together with LMI and Kreftforeningen.
Immunitrack has been awarded a grant from Eurostars to develop their prediction tool for cancer vaccines.
The Japanese tech giant NEC Corporation has acquired OncoImmunity AS.
We are happy to welcome three new members to the board of Oslo Cancer Cluster. Find out what they had to say about entering their new positions.
The Nobel Laureate Dr James Allison and oncologist Dr Padmanee Sharma will become strategic advisors for our member Lytix BioPharma.
Oslo Cancer Cluster and its international partners organised the International Cancer Cluster Showcase (ICCS) on 3 June in Philadelphia.
Oslo Cancer Cluster member Ultimovacs entered the Oslo Stock Exchange on Monday 3 June 2019.
Nordic Nanovector raises NOK 225 million in private placements, has Phase II clinical trials in 74 sites in 23 countries and prepares to commercialize the company.
Biobanks – the powerful tools in cancer research you may have never heard of.
We asked four MBA students from Cambridge University to evaluate how patient recruitment practices in Norway can be improved.
Why are legal services an important part of Oslo Cancer Cluster? We asked Andrew Wright from Potter Clarkson to explain why they became a member.
Oslo Cancer Cluster proudly presents the new members who have joined our organisation during the first quarter of 2019.
A second group of patients have been added to an ongoing phase II clinical study of a drug combination to treat lung cancer.
How can the voices of cancer patients be heard when evaluating new methods of treatment?
The laboratories at Oslo Cancer Cluster Incubator are expanding to meet increasing demand from members.
Dr. Jon Amund Kyte at Oslo University Hospital aims to bring more and better clinical trials to Norway.
Targovax, one of the members of Oslo Cancer Cluster, has begun an expansion patient group in the clinical trial of a drug to treat skin cancer. The company Targovax is developing immune activators to target solid tumours that are difficult to treat. The drug in question, called ONCOS-102, is aimed at patients with malignant melanoma (skin […]
Vaccibody and Roche have started a new collaboration to investigate a drug combination for patients with advanced cervical cancer.
Contact us >
Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines.
We are a national non-profit member organization with about 90 members. Our members are Norwegian and international companies, research and financial institutions, university hospitals and organizations – all working in the cancer field.